ImmunityBio Shareholder Class Action Filed Over Securities Misrepresentation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 07 2026
0mins
Should l Buy IBRX?
Source: Globenewswire
- Class Action Initiated: Bernstein Liebhard LLP announces a class action lawsuit on behalf of investors who purchased ImmunityBio (NASDAQ: IBRX) securities between January 19, 2026, and March 24, 2026, alleging misrepresentations regarding the capabilities of the company's lead biologic product, ANKTIVA, which may have resulted in investor losses.
- Lawsuit Details: Investors who acquired ImmunityBio securities during the specified period and suffered losses can file papers to serve as lead plaintiff by May 26, 2026, with the lead plaintiff representing the interests of other class members in the litigation.
- Fee Arrangement: All representation is on a contingency fee basis, meaning shareholders incur no fees or expenses, which lowers the barrier for investor participation and encourages more affected shareholders to join the lawsuit.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times in The National Law Journal's “Plaintiffs’ Hot List” for its success in handling hundreds of class actions, demonstrating its strong capabilities in securities litigation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.700
Low
5.00
Averages
7.33
High
9.00
Current: 7.700
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Lowey Dannenberg Investigates ImmunityBio for Potential Securities Violations
- Legal Investigation Launched: Lowey Dannenberg P.C. is investigating ImmunityBio Inc. for potential violations of federal securities laws, focusing on the accuracy and completeness of information disclosed to investors.
- Lawsuit Background: A complaint filed on March 26, 2026, alleges that ImmunityBio and its executives misrepresented Anktiva's capabilities, resulting in materially false and misleading statements about the company's business and prospects.
- Investor Losses: Attorney Andrea Farah indicated that investors who suffered losses exceeding $100,000 in ImmunityBio securities are encouraged to contact them to learn about eligibility for participation, highlighting potential legal liabilities and a decline in investor confidence.
- Reputational Risk: This investigation could negatively impact ImmunityBio's market performance, particularly as the company faces legal challenges, potentially leading to diminished investor confidence in its future business outlook.
See More
ImmunityBio Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: ImmunityBio, Inc. (IBRX) is facing a securities fraud class action lawsuit for material misstatements and omissions regarding its lead biologic product, Anktiva, during the period from January 19 to March 24, 2026, which has shaken investor confidence.
- Stock Price Drop: Following an FDA warning on March 24, 2026, regarding misleading claims about Anktiva, ImmunityBio's stock plummeted by 21.12%, closing at $7.42 per share, reflecting significant market concerns about the company's future prospects.
- Investor Action: Affected investors are urged to file for lead plaintiff status by May 26, 2026, to represent other investors in the lawsuit, indicating a crisis of trust in the company's management.
- Legal Support: Kessler Topaz Meltzer & Check, LLP is offering free consultations and encouraging investors to reach out for more information on how to participate in the lawsuit, demonstrating a commitment to protecting investor rights.
See More
Anktiva's New Data Sparks Attention Amid Psychedelic Push
- Trump's Policy Support: Founder Patrick Soon-Shiong stated that Trump “can make huge advances in transforming the health of Americans” following a White House push for psychedelic therapy research, potentially enhancing Anktiva's market acceptance.
- Breast Cancer Recurrence Risk Data: Soon-Shiong highlighted evidence linking lymphopenia to over a 2x increased risk of recurrence in early-stage breast cancer patients, emphasizing the importance of monitoring lymphocyte counts, which could drive clinical applications of related treatments.
- Post-COVID Immune Function Research: Plans for further clinical trials are underway to explore whether post-COVID immune dysfunction associated with T-cell exhaustion can be reversed, with Anktiva, an IL-15-based immunotherapy, potentially playing a key role in this process.
- Improved Market Sentiment: Following the news, retail sentiment for IBRX shifted from 'bearish' to 'neutral', with message volumes increasing by 70% over the week, indicating growing investor confidence in Anktiva's future potential.
See More
Class Action Lawsuit Filed Against ImmunityBio, Inc.
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) and certain officers, aiming to recover damages for investors who purchased securities between January 19 and March 24, 2026, reflecting strong investor concerns over potential fraud.
- Allegations: The complaint alleges that the defendants materially overstated Anktiva's capabilities and failed to disclose adverse facts regarding the company's business and prospects, which could severely undermine investor confidence and lead to significant stock price volatility.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by May 26, 2026, to share in any potential recovery from the lawsuit, indicating active participation and protection of their rights in the legal process.
- Law Firm's Strength: Bronstein, Gewirtz & Grossman LLC is recognized for recovering hundreds of millions for investors, emphasizing its expertise in securities fraud class actions, aiming to restore investor capital and ensure corporate accountability, thereby enhancing overall market integrity.
See More
ImmunityBio Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, to apply as lead plaintiffs by May 26, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that ImmunityBio made false and misleading statements during the class period, particularly regarding Anktiva's capabilities, resulting in investor losses when the truth emerged, highlighting significant transparency and compliance issues within the company.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, having achieved the largest securities class action settlement against a Chinese company in 2017, underscoring its leadership in the field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record rather than relying on intermediaries, ensuring they receive the best representation in the class action to protect their rights.
See More
Vertex Pharmaceuticals Stock Performance Strong
- Investment Recommendation: Jim Cramer highlighted Vertex Pharmaceuticals' strong stock performance, suggesting that buying early was a good decision, reflecting market confidence in its future growth and potentially attracting more investor interest.
- Industry Challenges: Oddity Tech's performance fell short of expectations, with Cramer admitting he underestimated the industry's complexities, indicating that market confidence in the company may be waning, prompting investors to carefully assess its future potential.
- Risk Assessment: ImmunityBio faces uncertainty, with Cramer emphasizing the need to observe how it resolves current issues, which could impact its stock price trajectory, necessitating vigilance from investors to navigate potential risks.
- Buying Opportunity: Copart is viewed as undervalued, with Cramer suggesting it represents a good buying opportunity, likely attracting investors looking for undervalued stocks and enhancing market interest in the company.
See More
Lowey Dannenberg Investigates ImmunityBio for Potential Securities Violations
- Legal Investigation Launched: Lowey Dannenberg P.C. is investigating ImmunityBio Inc. for potential violations of federal securities laws, focusing on the accuracy and completeness of information disclosed to investors.
- Lawsuit Background: A complaint filed on March 26, 2026, alleges that ImmunityBio and its executives misrepresented Anktiva's capabilities, resulting in materially false and misleading statements about the company's business and prospects.
- Investor Losses: Attorney Andrea Farah indicated that investors who suffered losses exceeding $100,000 in ImmunityBio securities are encouraged to contact them to learn about eligibility for participation, highlighting potential legal liabilities and a decline in investor confidence.
- Reputational Risk: This investigation could negatively impact ImmunityBio's market performance, particularly as the company faces legal challenges, potentially leading to diminished investor confidence in its future business outlook.
See More
ImmunityBio Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: ImmunityBio, Inc. (IBRX) is facing a securities fraud class action lawsuit for material misstatements and omissions regarding its lead biologic product, Anktiva, during the period from January 19 to March 24, 2026, which has shaken investor confidence.
- Stock Price Drop: Following an FDA warning on March 24, 2026, regarding misleading claims about Anktiva, ImmunityBio's stock plummeted by 21.12%, closing at $7.42 per share, reflecting significant market concerns about the company's future prospects.
- Investor Action: Affected investors are urged to file for lead plaintiff status by May 26, 2026, to represent other investors in the lawsuit, indicating a crisis of trust in the company's management.
- Legal Support: Kessler Topaz Meltzer & Check, LLP is offering free consultations and encouraging investors to reach out for more information on how to participate in the lawsuit, demonstrating a commitment to protecting investor rights.
See More
Anktiva's New Data Sparks Attention Amid Psychedelic Push
- Trump's Policy Support: Founder Patrick Soon-Shiong stated that Trump “can make huge advances in transforming the health of Americans” following a White House push for psychedelic therapy research, potentially enhancing Anktiva's market acceptance.
- Breast Cancer Recurrence Risk Data: Soon-Shiong highlighted evidence linking lymphopenia to over a 2x increased risk of recurrence in early-stage breast cancer patients, emphasizing the importance of monitoring lymphocyte counts, which could drive clinical applications of related treatments.
- Post-COVID Immune Function Research: Plans for further clinical trials are underway to explore whether post-COVID immune dysfunction associated with T-cell exhaustion can be reversed, with Anktiva, an IL-15-based immunotherapy, potentially playing a key role in this process.
- Improved Market Sentiment: Following the news, retail sentiment for IBRX shifted from 'bearish' to 'neutral', with message volumes increasing by 70% over the week, indicating growing investor confidence in Anktiva's future potential.
See More
Class Action Lawsuit Filed Against ImmunityBio, Inc.
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) and certain officers, aiming to recover damages for investors who purchased securities between January 19 and March 24, 2026, reflecting strong investor concerns over potential fraud.
- Allegations: The complaint alleges that the defendants materially overstated Anktiva's capabilities and failed to disclose adverse facts regarding the company's business and prospects, which could severely undermine investor confidence and lead to significant stock price volatility.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by May 26, 2026, to share in any potential recovery from the lawsuit, indicating active participation and protection of their rights in the legal process.
- Law Firm's Strength: Bronstein, Gewirtz & Grossman LLC is recognized for recovering hundreds of millions for investors, emphasizing its expertise in securities fraud class actions, aiming to restore investor capital and ensure corporate accountability, thereby enhancing overall market integrity.
See More
ImmunityBio Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, to apply as lead plaintiffs by May 26, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that ImmunityBio made false and misleading statements during the class period, particularly regarding Anktiva's capabilities, resulting in investor losses when the truth emerged, highlighting significant transparency and compliance issues within the company.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, having achieved the largest securities class action settlement against a Chinese company in 2017, underscoring its leadership in the field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record rather than relying on intermediaries, ensuring they receive the best representation in the class action to protect their rights.
See More
Vertex Pharmaceuticals Stock Performance Strong
- Investment Recommendation: Jim Cramer highlighted Vertex Pharmaceuticals' strong stock performance, suggesting that buying early was a good decision, reflecting market confidence in its future growth and potentially attracting more investor interest.
- Industry Challenges: Oddity Tech's performance fell short of expectations, with Cramer admitting he underestimated the industry's complexities, indicating that market confidence in the company may be waning, prompting investors to carefully assess its future potential.
- Risk Assessment: ImmunityBio faces uncertainty, with Cramer emphasizing the need to observe how it resolves current issues, which could impact its stock price trajectory, necessitating vigilance from investors to navigate potential risks.
- Buying Opportunity: Copart is viewed as undervalued, with Cramer suggesting it represents a good buying opportunity, likely attracting investors looking for undervalued stocks and enhancing market interest in the company.
See More
